Events & Presentations

Events & Presentations

Upcoming Events

There are no upcoming events available at this time.

Past Events

Oct 05 - Oct 09, 2025
Dublin, Ireland
May 12 - May 14, 2025
Mainz, Germany
Jun 17, 2021

Corporate Presentation

Date Type Program Title File
Jun 01, 2026
Corporate Presentation All Programs
Immatics Corporate Presentation June 2026

Presentations

Date Type Program Title File
Jun 01, 2026
Clinical Data Anzu-cel (IMA203) PRAME Cell Therapy
ASCO Phase 1b Data on Anzu-cel PRAME Cell Therapy in Metastatic Melanoma - Clinical Activity and Response Dynamics
May 31, 2026
Clinical Data IMA203CD8 PRAME Cell Therapy
ASCO Phase 1 Data on Anzu-cel and IMA203CD8 PRAME Cell Therapy in Synovial Sarcoma
May 31, 2026
Clinical Data IMA401 MAGEA4/8 Bispecific
ASCO Phase 1 Data on IMA401 Targeting MAGEA4/8 in Solid Tumors
May 30, 2026
Clinical Data IMA203CD8 PRAME Cell Therapy
ASCO Phase 1 Data on IMA203CD8 Cell Therapy in Gynecologic Cancers
Dec 11, 2025
Clinical Data IMA203CD8 PRAME Cell Therapy
IMA203CD8 Cell Therapy in PRAME-positive Solid Tumors - Phase 1a Dose Escalation Clinical Data Update
Nov 12, 2025
Clinical Data TCR Bispecifics
Phase 1a Dose Escalation Data on IMA402 PRAME Bispecific & IMA401 MAGEA4/8 Bispecific
Oct 20, 2025
Clinical Data Anzu-cel (IMA203) PRAME Cell Therapy
ESMO Anzu-cel PRAME Cell Therapy Phase 1b Data in Patients with Metastatic Uveal Melanoma
May 31, 2025
Clinical Data IMA203 PRAME Cell Therapy
IMA203 PRAME Cell Therapy Phase 1b Data in Patients with Metastatic Melanoma
May 31, 2025
Clinical Data IMA203 PRAME Cell Therapy
ASCO IMA203 PRAME Cell Therapy Phase 1b Data in Patients with Metastatic Melanoma
Nov 08, 2024
Clinical Data IMA203CD8 PRAME Cell Therapy (GEN2)
Enhanced Pharmacology Data of Next-generation IMA203CD8 TCR-T Monotherapy Targeting PRAME

Archive

Date Title File
Nov 18, 2024
TCR Bispecific Molecule IMA402 Targeting PRAME - Phase 1 Dose Escalation Clinical Data Update
Source
IMA402 PRAME Bispecific
Nov 08, 2024
IMA203 TCR-T Targeting PRAME Shows Deep and Durable Anti-Tumor Activity in Heavily Pretreated Solid Cancer Patients
Source
IMA203 PRAME Cell Therapy
Oct 10, 2024
IMA203 TCR-T Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion Clinical Data Update
Sep 16, 2024
IMA401 Targeting MAGEA4/8 - Phase 1 Dose Escalation Clinical Data Update
Source
IMA401 MAGEA4/8 Bispecific
Nov 08, 2023
IMA203 TCR-T Targeting PRAME in PD1 Refractory Metastatic Melanoma
Nov 08, 2023
IMA203 & IMA203CD8 TCR-T Monotherapy Targeting PRAME - Phase 1 Interim Data Update
May 02, 2023
IMA203 TCR-T Monotherapy Targeting PRAME - Phase 1b Cohort A Interim Data Update
Oct 10, 2022
IMA203 TCR-T Targeting PRAME - Monotherapy Interim Data Update
Nov 13, 2021
Safety and Anti-Tumor Activity of TCR-Engineered Autologous, PRAME-Directed T Cells Across Multiple Advanced Solid Cancers at Low Doses – Clinical Update on the ACTengine® IMA203 Trial
Nov 09, 2021
IMA200 TCR-T Programs Interim Phase 1a Update